This webcast was originally recorded May 21, 2019. Follow this link for webcast with Hebrew Subtitles.
Are you interested in optimizing your treatment?
In ‘Optimizing GIST Treatment’, this world-renown GIST expert from Europe will share his wealth of experience and insight about how he has helped patients live longer, and how he consults with fellow physicians on the best treatment plan for their patients. Dr. Peter Reichardt is Assistant Professor and Head of the Department of Oncology and Palliative Care at the Helios Klinikum Berlin-Buch in Berlin, Germany, and is Director of the Cancer Center Berlin-Buch and the Sarcoma Center Berlin-Brandenburg.
In this webcast Dr. Reichardt will discuss surgery for metastatic disease, imatinib plasma level testing, and the management of side effects. He will also cover dosing, dose escalation and dose schedules, and will explain mutations and the importance of mutational testing.
About the Presenter:
Dr. Peter Reichardt trained in internal medicine and haematology/oncology at the University of Heidelberg and at the MD Anderson Cancer Center, Houston, TX, USA. From 1992 to 2007, he was a consultant at the Charité University Hospital in Berlin. Dr. Reichardt has led and conducted multiple clinical trials in bone sarcomas, soft tissue sarcomas, and gastrointestinal stromal tumours in the adjuvant, advanced, and refractory settings.
Dr. Reichardt is a co-author of the current European Society for Medical Oncology (ESMO) guidelines for the management of GIST, soft tissue and bone sarcomas and a member of the ESMO Sarcoma Faculty. He is chairman of the Scientific Committee of the GIST and Sarcoma patients’ organization ‘Das Lebenshaus’, a member of the Medical Board of the MAX Foundation, and a member of the Life Raft Group’s Global GIST Advisory Team. Dr. Reichardt has contributed to numerous publications on soft tissue sarcoma and GIST management in leading oncology journals.